TOVX Theriva Biologics Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: TOVX

Price (delayed)

$0.2347

Market cap

$10.77M

P/E Ratio

0.32

Dividend/share

N/A

EPS

$0.73

Enterprise value

$2.94M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 38

Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a ...

Highlights
Theriva Biologics's EPS has soared by 165% from the previous quarter and by 115% YoY
The net income has soared by 61% YoY and by 46% QoQ
The debt has increased by 23% year-on-year but it has declined by 3.8% since the previous quarter
TOVX's equity is down by 21% from the previous quarter but it is up by 15% YoY
The quick ratio has decreased by 33% from the previous quarter and by 4.1% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.syntheticbiologics.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of TOVX

TOVX stock price

How has the Theriva Biologics stock price performed over time
Intraday
1.69%
1 week
3.85%
1 month
-0.13%
1 year
-41.09%
YTD
11.55%
QTD
-6.2%

Financial performance

How have Theriva Biologics's revenue and profit performed over time
Revenue
$300,000
Gross profit
$300,000
Operating income
-$11.93M
Net income
-$11.62M
Gross margin
100%
Net margin
-3,872.7%
The net income has soared by 61% YoY and by 46% QoQ
The company's operating income has surged by 60% YoY and by 45% QoQ
The net margin has increased by 46% since the previous quarter
Theriva Biologics's operating margin has increased by 45% from the previous quarter

Price vs fundamentals

How does TOVX's price correlate with its fundamentals

Growth

What is Theriva Biologics's growth rate over time

Valuation

What is Theriva Biologics stock price valuation
P/E
0.32
P/B
0.88
P/S
35.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.81
Theriva Biologics's EPS has soared by 165% from the previous quarter and by 115% YoY
TOVX's P/B is 118% above its 5-year quarterly average of 0.4 and 45% above its last 4 quarters average of 0.6
TOVX's equity is down by 21% from the previous quarter but it is up by 15% YoY

Efficiency

How efficient is Theriva Biologics business performance
The return on invested capital has surged by 60% year-on-year and by 46% since the previous quarter
The ROA has soared by 55% YoY and by 43% from the previous quarter
Theriva Biologics's ROS has increased by 46% from the previous quarter
The ROE is up by 45% QoQ and by 38% YoY

Dividends

What is TOVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TOVX.

Financial health

How did Theriva Biologics financials performed over time
The total assets is 54% more than the total liabilities
The quick ratio has decreased by 33% from the previous quarter and by 4.1% YoY
Theriva Biologics's current ratio has decreased by 31% from the previous quarter and by 5% YoY
The debt is 71% smaller than the equity
The debt has increased by 23% year-on-year but it has declined by 3.8% since the previous quarter
TOVX's equity is down by 21% from the previous quarter but it is up by 15% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.